Zealand Pharma AS (fra:22Z) Share Price

Company Profile

Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNK
T: +45 88773600
E: [email protected]
https://www.zealandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578

Recommended

These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.

Morningstar | 11 November 2026

There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.

Malik Ahmed Khan, CFA | 11 November 2026

Strong fundamentals meet a demanding valuation.

Esther Holloway | 11 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,243.40	47.90	-0.52%
CAC 40	8,332.87	54.28	0.66%
DAX 40	26,662.77	315.32	1.20%
Dow JONES (US)	52,486.49	254.60	0.49%
FTSE 100	10,835.47	83.88	0.78%
HKSE	24,044.48	271.44	-1.12%
NASDAQ	25,466.19	400.32	1.60%
Nikkei 225	61,592.02	343.43	0.56%
NZX 50 Index	14,256.38	76.52	0.54%
S&P 500	7,619.38	98.45	1.31%
S&P/ASX 200	9,111.10	42.10	-0.46%
SSE Composite Index	3,681.69	1.04	0.03%